Ozempic (semaglutide) is approved by the FDA:
- For adults with type 2 diabetes to lower blood glucose (sugar), along with diet and exercise.
- To reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes and known heart disease.
Wegovy (semaglutide) is approved by the FDA for chronic (long-term) weight management in adults and children 12 years and older, along with diet and exercise.
- Adults should have an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related health condition (for example: high blood pressure, type 2 diabetes mellitus, or high cholesterol).
- Children 12 years and older should have an initial BMI at the 95th percentile or greater for age and sex (obesity).
- Wegovy is also approved reduce the risk of heart attack, stroke and heart-related death in people with cardiovascular (heart, blood vessel) disease.